Overview
Triple receptor agonist (GLP-1/GIP/glucagon), composed of a polypeptide skeleton. It is currently in phase III clinical trials and has not yet been officially approved by the FDA. Achieve stronger metabolic regulation by activating three metabolism-related receptors simultaneously.
| Chemical Class | GLP-1/GIP/glucagon triple agonist |
| Dosage Form | injection pen |
| Specification | 1mg/3mg/6mg/9mg/12mg |
| Dosing Frequency | Weekly subcutaneous injection |
| Storage | Refrigerate at 2-8°C |
Mechanism of Action
GLP-1/GIP dual channel: same as TR5
Glucagon receptor activation: increases energy consumption and promotes lipolysis
Triple synergy: hypoglycemic + weight loss + increased metabolic rate
Relevant to indications: The triple mechanism theoretically has greater potential for metabolic regulation than dual agonists.
| Indication | Mechanism | Evidence |
|---|
| Blood sugar management support | triple receptor activation | Clinical Phase III |
| Weight management support | Lipolysis + increased energy expenditure | Clinical Phase III |
| Increased metabolic rate | Glucagon receptor energy metabolism | clinical exploration |
Dosage & Administration
Safety Information
Regulatory Status
NMPA (China)Approved
FDAstatus to be confirmed
WADAnot disabled
Drug Interactions
FAQ
Q1: How long will it take to see changes?
The change time varies greatly depending on the product mechanism and personal physique. It is recommended to refer to clinical trial data of similar products.
Q2: Will it rebound after deactivation?
Depends on product category and individual maintenance regimen. Metabolic products may gradually return to baseline; repair products are usually long-lasting.
Q3: Can it be used with other supplements?
In most cases, it is possible, but care should be taken to avoid overlapping products with the same mechanism. Please refer to Module 13 ‘Drug Interactions’ for details.
Q4: Why is it banned for athletes?
Some products are included in WADA’s banned list. Athletes should check the latest WADA list before use.
Q5: What is the difference from XX products?
Please see the competitor comparison matrix for this category.
Q6: Are there any side effects?
Please see Module 12 ‘Safety and Toxicology Details’.
Q7: Does it need to be used for a long time?
Depends on product category and target. Please refer to Module 10 ‘Dosage and Administration’ for treatment recommendations.
Q8: Who is not suitable?
Please refer to Module 8 ‘Contraindications and Precautions’.
Disclaimer: This product is intended for research purposes only. Not for human consumption or therapeutic use. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
